An interventional study of Tocilizumab in Corona Virus Disease 2019 (COVID-19), sponsored by University of Lahore. Completed at 1 site in Pakistan. Per ClinicalTrials.gov, last updated 2020-12-31.
Sponsored by University of Lahore · Not applicable, Interventional, and Supportive care
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 200 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →University of Lahore is the lead sponsor of 223 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy
Exclusion Criteria:
Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent
Drug: Tocilizumab
Drug: Tocilizumab
Drug: Tocilizumab
Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
Also known as: Remdesivir, Standard treatment with Antibiotic, oxygen, Vitamin C, Statins, No treatment is given to control group
Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen
Time frame: 7 days
Hospital stay
Time frame: 15 days
Oxygen demand
Time frame: 7-15 days
Viral load
by RT-PCR
Time frame: 7-15 days
Plan to share: Undecided — statistical analysis, results
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Lahore